Treatment adherence
Digital pills cut blood pressure faster
Open access · cc by · source: Europe PMC
Patients with uncontrolled hypertension and type 2 diabetes using digital medicines had larger 4-week SBP drops than usual care.
Study at a glance
- Design
- RCT — Open-label cluster-randomized three-arm pilot: 4-week DMO, 12-week DMO, usual care
- N
- N=109 · Modified ITT (40 / 40 / 29) across 13 US primary-care sites
- Population
- Adults with uncontrolled hypertension and type 2 diabetes in US primary care
- Outcome
- SBP reduction, BP goal attainment, and LDL-C/HbA1c change to 12 weeks
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
DMO users had about 9 mm Hg greater SBP reduction by week 4, more patients at BP goal by week 12, and larger LDL-C declines; HbA1c also trended lower.
Methodology
A 12-week open-label cluster-randomized three-arm pilot at 13 US primary-care sites compared 4-week DMO, 12-week DMO, and usual care for uncontrolled HTN with T2DM.
Limitations
Long-term hard cardiovascular events, blinded placebo effects, or performance outside motivated primary-care clusters.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
ITT does not require individual randomisation. A 12-week open-label cluster-randomised pilot at 13 US primary-care sites found digital-medicine users had about 9 mm Hg greater SBP reduction by week 4, with more patients at BP goal by week 12. That is an effect of site-level assignment, unblinded, and not a hard cardiovascular-event result. A produce-app RCT that increased fruit intake by about three pieces per week also reported high attrition — another ITT-with-missing-data problem.
Evidence for the claim as stated.
A 12-week open-label three-arm pilot cluster-randomised 13 US primary-care sites to 4-week digital-medicine offering, 12-week offering, or usual care for uncontrolled hypertension with type 2 diabetes. Digital-medicine users had about 9 mm Hg greater SBP reduction by week 4, more patients at BP goal by week 12, and larger LDL-C declines; HbA1c trended lower. The design cannot speak to long-term cardiovascular events or to blinded placebo effects.
Evidence for the claim as stated.
Open-label clinical clusters and community structural trials ask different causal questions under the same design name. Digital medicines at 13 sites cut SBP by about 9 mm Hg without placebo control; Mashhad trained 35 physicians and followed 240 patients for literacy and BP; SASA! randomised Kampala communities to a norm-change programme. Blinding a village activist campaign is not the same problem as blinding a digital pill, and neither is an individually randomised ITT drug trial.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
Open-label clinical clusters and community structural trials ask different causal questions under the same design name. Digital medicines at 13 sites cut SBP by about 9 mm Hg without placebo control; Mashhad trained 35 physicians and followed 240 patients for literacy and BP; SASA! randomised Kampala communities to a norm-change programme. Blinding a village activist campaign is not the same problem as blinding a digital pill, and neither is an individually randomised ITT drug trial.
Related papers in this topic
Same topic cluster — not a recommendation engine.